Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.

@article{Savica2007PhosphateSS,
  title={Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.},
  author={Vincenzo Savica and Lorenzo A. Cal{\`o} and Renato Caldarera and Adelaide Cavaleri and Antonio Granata and Domenico Santoro and Rodolfo Savica and Ugo Muraca and Agostino Mallamace and Guido Bellinghieri},
  journal={Nephron. Physiology},
  year={2007},
  volume={105 3},
  pages={p52-5}
}
BACKGROUND/AIMS Hyperphosphatemia is recognized as contributing to the increased risk of cardiac death in end-stage renal disease (ESRD) and hemodialysis (HD) patients. Currently available pharmacologic treatment for hyperphosphatemia is based on phosphate binders but, despite treatment, only half of the patients fall within the range for serum phosphorus of the K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches in order to reduce serum phosphate. Salivary… CONTINUE READING